NCT00116467

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 55 (planned)
• Sponsor: Cell Genesys · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Conditions

• Acute Myelogenous Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)

Timeline

• Start date: 2001-03-01
• Completion: 2006-01-01
• First posted: 2005-06-30
• Last updated: 2007-12-24

Locations

4 sites across 1 country: United States